BRPI0705630F8 - Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof - Google Patents

Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof

Info

Publication number
BRPI0705630F8
BRPI0705630F8 BRC10705630A BRPI0705630A BRPI0705630F8 BR PI0705630 F8 BRPI0705630 F8 BR PI0705630F8 BR C10705630 A BRC10705630 A BR C10705630A BR PI0705630 A BRPI0705630 A BR PI0705630A BR PI0705630 F8 BRPI0705630 F8 BR PI0705630F8
Authority
BR
Brazil
Prior art keywords
gene vaccine
liposomal gene
liposomal
administration
production process
Prior art date
Application number
BRC10705630A
Other languages
Portuguese (pt)
Inventor
A M Coelho Castelo Arlete
Lopes Silva Célio
Gaziola De La Torre Lucimara
Helena Andrade Santana Maria
Silva Rosada Rogério
Original Assignee
Univ Estadual Campinas Unicamp
Univ Sao Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Estadual Campinas Unicamp, Univ Sao Paulo filed Critical Univ Estadual Campinas Unicamp
Priority to BRC10705630A priority Critical patent/BRPI0705630F8/en
Priority to PCT/BR2008/000387 priority patent/WO2009073941A2/en
Publication of BRPI0705630A2 publication Critical patent/BRPI0705630A2/en
Publication of BRPI0705630E2 publication Critical patent/BRPI0705630E2/en
Publication of BRPI0705630B1 publication Critical patent/BRPI0705630B1/en
Publication of BRPI0705630F1 publication Critical patent/BRPI0705630F1/pt
Publication of BRPI0705630B8 publication Critical patent/BRPI0705630B8/en
Publication of BRPI0705630F8 publication Critical patent/BRPI0705630F8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma. a presente concretização se refere a um processo de obtenção de um produto funcional destinado para emprego na área de saúde, tanto humana como animal, para prevenção da tuberculose e de outras doenças infecciosas causadas ou não por micobactérias. mais especificamente, o referido produto consiste em uma vacina gênica, a qual apresenta como principais vantagens, a redução da dose, a frequência de administração, quando comparada ao polinucleotídeo livre, a administração por via nasal, não invasiva, facilitando a aplicação e minimizando o desconforto do paciente, além de não oferecer riscos relativos à utilização de microrganismos vivos atenuados.process of production of liposomal gene vaccine, liposomal gene vaccine and use thereof. the present embodiment refers to a process for obtaining a functional product intended for use in the health area, both human and animal, for the prevention of tuberculosis and other infectious diseases caused or not by mycobacteria. more specifically, said product consists of a gene vaccine, which has as main advantages, the reduction of the dose, the frequency of administration, when compared to the free polynucleotide, the administration by nasal route, non-invasive, facilitating the application and minimizing the patient discomfort, in addition to not offering risks related to the use of live attenuated microorganisms.

BRC10705630A 2007-12-12 2007-12-12 Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof BRPI0705630F8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRC10705630A BRPI0705630F8 (en) 2007-12-12 2007-12-12 Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof
PCT/BR2008/000387 WO2009073941A2 (en) 2007-12-12 2008-12-12 Ternary liposomal composition containing a polynucleotide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRC10705630A BRPI0705630F8 (en) 2007-12-12 2007-12-12 Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof

Publications (6)

Publication Number Publication Date
BRPI0705630A2 BRPI0705630A2 (en) 2010-12-28
BRPI0705630E2 BRPI0705630E2 (en) 2011-03-09
BRPI0705630B1 BRPI0705630B1 (en) 2020-09-24
BRPI0705630F1 BRPI0705630F1 (en) 2021-03-30
BRPI0705630B8 BRPI0705630B8 (en) 2021-05-25
BRPI0705630F8 true BRPI0705630F8 (en) 2022-01-18

Family

ID=40755920

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC10705630A BRPI0705630F8 (en) 2007-12-12 2007-12-12 Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof

Country Status (2)

Country Link
BR (1) BRPI0705630F8 (en)
WO (1) WO2009073941A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2661253T3 (en) * 2011-01-04 2017-08-31 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
TW202228727A (en) * 2020-10-01 2022-08-01 德商拜恩迪克公司 Preparation and storage of liposomal rna formulations suitable for therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
US6110745A (en) * 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
EP1845944A4 (en) * 2005-02-08 2011-07-27 Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America PHARMACEUTICAL COMPOSITIONS

Also Published As

Publication number Publication date
WO2009073941A3 (en) 2009-08-27
BRPI0705630B8 (en) 2021-05-25
BRPI0705630F1 (en) 2021-03-30
BRPI0705630E2 (en) 2011-03-09
WO2009073941A2 (en) 2009-06-18
BRPI0705630B1 (en) 2020-09-24
BRPI0705630A2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
BR112015006623A2 (en) laquinimod and pridopidine for the treatment of neurodegenerative diseases
BRPI1011220A2 (en) pharmaceutical composition, methods of treating a disease or disorder, for the respiratory administration of two or more active agents, for the respiratory administration of a combination of active agents, and for preparing a suitable composition.
UA104320C2 (en) Pharmaceutical composition based on mitochondria-targeted antioxidants for use in medical and veterinary ophthalmology
BR112015007814A2 (en) diagnosis, prevention and treatment of joint disease
BR112013022789A2 (en) pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
MX2010001401A (en) IMPROVED MEDICAL PRODUCTS, COVERED WITH PHARMACEUTICAL PREPARATIONS, THE PRODUCTION OF THE SAME AND THE USE OF THEM.
BR112014031394A2 (en) compositions and methods for transmucosal absorption
BR112015006093A2 (en) combination of rasagiline and pridopidine for the treatment of neurodegenerative disorders, particularly in huntington's disease
BR112012030337A2 (en) vaccines comprising cholesterol and cpg as exclusive carrier-adjuvant molecules and use thereof
BRPI0806392A8 (en) use of aclidinium, aclidinium, treatment or prevention method and pharmaceutical composition
BR112014031788A2 (en) compositions and methods for treating diabetes
BR112014011981A8 (en) ORAL SOLID PHARMACEUTICAL FORMULATIONS, THEIR PREPARATION PROCESSES AND USES
PL2081910T3 (en) Novel compounds
BR112017020039A2 (en) pharmaceutical composition, kit, method, process for preparing a pharmaceutical composition and solution
CL2008001820A1 (en) Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases.
BR112015006656A8 (en) compositions and methods for the treatment of heart failure in diabetic patients
HN2009003424A (en) (OXAZOLIDINON-5-IL-METIL) -2-TIOFEN-CARBOXAMIDAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
BR112012017300A2 (en) A process for preparing a biomass comprising plantaricin and its use in the medical field
GT201300125A (en) 1H-PIRAZOL-5-SUBSTITUTED SODIUM OLATO
BR112015006363A2 (en) pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
BR112013005226A2 (en) "Substituted n-phenethyltriazoloneacetamides and their use".
BRPI0705630F8 (en) Production process of liposomal gene vaccine, liposomal gene vaccine and use thereof
BR112014015578A8 (en) topical pharmaceutical compositions comprising bexarotene and a corticosteroid
BRPI0606140A2 (en) thiazolidinones, preparation and use as a medicine
CY1119308T1 (en) COMBINATIONS WITH A CIRCULATED FRAMEWORK Peptide

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA PARECER DE EXIGENCIA 6.22 NOTIFICADO NA RPI NO 2569 DE 31-03-2020, TENDO SIDO CONSTATADO QUE O MESMO NAO FOI DISPONIBILIZADO, ASSIM REPUBLICO A REFERIDA PUBLICACAO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09A Decision: intention to grant [chapter 9.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 13A ANUIDADE.

B24D Patent annual fee: restoration after fee payment

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.